The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon-gamma as a therapeutic agent for proliferative eye diseases.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel iPSC differentiation protocol for generating fibroblasts and endothelial cells.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a transgenic mouse model for X-linked retinoschisis (XLRS).
Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA.
X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases.